Well then. That removes one meaningful overhang heading into the next phase of Iovance's commercial execution.
Circular Reference
Posts (404)
During the earnings call, Raj referenced an end-of-Q4 BLA submission, and Fred clarified that the filing would occur in 2027.
Was Raj referring to Q1 2027?
Maybe the BLA gets submitted in the first few weeks of January before the JPM conference.
It wants to goooo
Lung FDA final App will be ready to submit in Dec. ‘26. But they are waiting until ‘27.
Iovance partnered with UK-based Cell and Gene Therapy Catapult to research next-generation smart manufacturing technology, with an option to license the platform. The potential benefit is more automated, efficient, and scalable TIL production, which could reduce manufacturing costs, improve margins, and support future growth—but specific implementation and financial benefits haven’t been disclosed.
SITC overview:
Melanoma survival: Lifileucel projects meaningful long-term survival advantages over standard of care.
Sarcoma: A 37.5% response rate in eight heavily pretreated patients suggests
potential expansion beyond melanoma.
Commercial experience: Four responses among four initially evaluable real-world patients, including two complete responses, supports commercial feasibility, although durability and tolerability remain concerns.
IOVANCE – SITC Abstract #346
Abstract #346 evaluates Iovance’s lifileucel in patients with advanced melanoma who have progressed following anti-PD-1 therapy, compared with standard of care.
- Tuesday, November 3, 2026 – 6:00 a.m. PT (9:00 a.m. ET): Full abstract release.
- Friday, November 6, 2026 – 6:00 a.m. PT (9:00 a.m. ET): Additional poster/ePoster data release.
Tuesday is the key date to watch. The full abstract will give investors an opportunity to evaluate the underlying data ahead of the conference presentation.
IOVANCE – SITC Abstract #346
Abstract #346 evaluates Iovance’s lifileucel in patients with advanced melanoma who have progressed following anti-PD-1 therapy, compared with standard of care.
- Tuesday, November 3, 2026 – 6:00 a.m. PT (9:00 a.m. ET): Full abstract release.
- Friday, November 6, 2026 – 6:00 a.m. PT (9:00 a.m. ET): Additional poster/ePoster data release.
Tuesday is the key date to watch. The full abstract will give investors an opportunity to evaluate the underlying data ahead of the conference presentation.